Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Net Cash Flow (2023 - 2026)

Compass Therapeutics' Net Cash Flow history spans 4 years, with the latest figure at $24.5 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 1107.19% to $24.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.1 million, a 18.73% decrease, with the full-year FY2025 number at -$12.8 million, down 166.68% from a year prior.
  • Net Cash Flow hit $24.5 million in Q1 2026 for Compass Therapeutics, up from -$15.6 million in the prior quarter.
  • Over the last five years, Net Cash Flow for CMPX hit a ceiling of $24.5 million in Q1 2026 and a floor of -$18.2 million in Q2 2025.
  • Historically, Net Cash Flow has averaged $1.6 million across 4 years, with a median of -$2.4 million in 2025.
  • Biggest five-year swings in Net Cash Flow: crashed 354.65% in 2025 and later surged 1107.19% in 2026.
  • Tracing CMPX's Net Cash Flow over 4 years: stood at -$6.2 million in 2023, then skyrocketed by 198.64% to $6.1 million in 2024, then tumbled by 354.65% to -$15.6 million in 2025, then skyrocketed by 257.52% to $24.5 million in 2026.
  • Business Quant data shows Net Cash Flow for CMPX at $24.5 million in Q1 2026, -$15.6 million in Q4 2025, and $23.4 million in Q3 2025.